"The highest estimates for aggregated exposure to BPA from both dietary and non-dietary sources are 3 to 5 times lower than the TDI, depending on the age group."
"The highest estimates for aggregated exposure to BPA from both dietary and non-dietary sources are 3 to 5 times lower than the TDI, depending on the age group."
"BPA is safe at the current levels occuring in food"
"Receipts containing BPA do not pose a risk to consumers or cashiers"
"Levels of BPA in the human body are very low, indicating that BPA is not accumulated in the body and is rapidly eliminated."
"BPA is safe at the current levels occuring in food"
"… the ingestion of BPA via food does not present a risk to consumers"
"Levels of BPA in the human body are very low, indicating that BPA is not accumulated in the body and is rapidly eliminated."
The EU Risk Assessment on bisphenol A (BPA) concluded that BPA and BPA-based products are safe. EU Risk Assessments are one element in the EU's Existing Substances Regulation to evaluate and control risks of chemical substances, one of the pre-cursors to REACH. They are widely recognised as the world's most rigorous scientific assessment of a substance's safety in existence today.
In the Risk Assessment Report on BPA published in June 2008, the European Commission concluded that products made from BPA, such as polycarbonate plastic and epoxy resins, are safe for consumers and the environment when used as intended.
For the BPA Risk Assessment independent scientific experts from the EU Members States considered several hundreds of studies that appeared during recent years, among them both small exploratory studies that do not follow established protocols, as well as comprehensive, statistically-robust studies following accepted international protocols and standards, such as the Good Laboratory Practice Directive. Overall, the studies also covered all potentially affected age groups of consumers including babies and small children.
This BPA Risk Assessment conclusion is consistent with conclusions of the scientific assessments of other regulatory bodies including the U.S. Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare.
The Risk Assessment was also the basis for the BPA dossier registration under REACH. The dossier is currently being re-evaluated by the European Chemicals Agency.
More information